Day One Biopharmaceuticals shared a post on LinkedIn:
”We are pleased to announce a new ex-U.S. licensing agreement with Ipsen to commercialize tovorafenib. This collaboration highlights our shared commitment to bring novel therapeutics to patients worldwide who have limited treatment options. Learn more.”